LX 22001
Alternative Names: LX-22001Latest Information Update: 20 Sep 2024
At a glance
- Originator Shandong Luoxin Pharmaceutical
- Class Antiulcers
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bleeding ulcer; Duodenal ulcer; Reflux oesophagitis
Most Recent Events
- 05 Aug 2024 Phase-I clinical trials in Bleeding ulcer (In volunteers) in China (IV) (NCT06561542; CTR20242538)
- 05 Aug 2024 Phase-I clinical trials in Duodenal ulcer (In volunteers) in China (IV) (NCT06561542; CTR20242538)
- 05 Aug 2024 Phase-I clinical trials in Reflux oesophagitis (In volunteers) in China (IV) (NCT06561542; CTR20242538)